A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Hypoxia-Inducible Factor-1 Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer
2006
Clinical Cancer Research
Purpose: To investigate the relationship of hypoxia-inducible factor-1a (HIF-1a) tumor expression in predicting the response to epirubicin and disease-free survival (DFS) in patients with breast cancer enrolled in a single institution trial of primary anthracycline and tamoxifen therapy. Experimental Design: The expression of HIF-1a was assessed by immunohistochemistry in 187 patients with T 2-4 N 0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin
doi:10.1158/1078-0432.ccr-05-2690
pmid:16899602
fatcat:e2jrpkzpejdgvoeoxrf4spgqjm